{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:11:46Z","timestamp":1794550306821,"version":"4.9.1"},"reference-count":61,"publisher":"Informa UK Limited","issue":"9","funder":[{"name":"Institute of Smart Healthcare Innovative Medical Sciences"},{"name":"Brain Korea 21 Four Program"},{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,9,2]]},"DOI":"10.1080\/14712598.2025.2556903","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T14:57:40Z","timestamp":1756825060000},"page":"935-946","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer"],"prefix":"10.1080","volume":"25","author":[{"given":"Jeesun","family":"Yoon","sequence":"first","affiliation":[{"name":"Seoul National University Hospital","place":["Seoul, Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital","place":["Seoul, Korea"]},{"name":"Seoul National University College of Medicine","place":["Seoul, Korea"]},{"name":"Seoul National University Graduate School","place":["Seoul, Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02576"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00095-5"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.104"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"e_1_3_6_11_1","unstructured":"Fda approves ivosidenib for advanced or metastatic cholangiocarcinoma 2021. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.5858\/2010-0454-RAR.1"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11157"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00924-9"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113564"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00242-5"},{"key":"e_1_3_6_19_1","unstructured":"Fda grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanidatamab-hrii-previously-treated-unresectable-or-metastatic-her2"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/35052073"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00171-0"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206007"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00621-0"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00336-3"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02010"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4090"},{"key":"e_1_3_6_28_1","unstructured":"Fda grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00140-2"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00606"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00335-1"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01193"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0028-1"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0657"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.12.008"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23948-6"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37029-3"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.818013"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04471-x"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59279-z"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.164"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104875"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4091"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.153"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1394"},{"key":"e_1_3_6_47_1","unstructured":"Zanidatamab (Ziihera) is authorised for use in the European Union. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ziihera"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1489"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00287-6"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.585"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2078"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104540"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1489"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06280-x"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000637"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.12.009"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1004"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30408"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0838"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0754"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14089"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.719217"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.629"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2556903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T06:31:15Z","timestamp":1758609075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2556903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"alternative-id":["10.1080\/14712598.2025.2556903"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2556903","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}